Local Injection of PRP During Repair of Disrupted Surgical Wounds

Role of Platelet Rich Plasma in Wound Healing Clinical Trial

Official title:

Local Injection of Autologous Platelet Rich Plasma During Repair of Disrupted Surgical Wounds at Obstetrics and Gynecology Department: A Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03781882
• Other study ID #: PRP surgical wounds
• Status: Completed
• Phase: N/A
• Start date: January 1, 2019
• Est. completion date: March 31, 2020

Study information

• Verified date: May 2020
• Source: Tanta University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with disrupted wounds will either managed as usual or managed by Platelet rich plasma local infiltration in the wound edges

Description:

The patients with disrupted surgical wounds will be cleansed, debrided and closed with infiltration of platelet rich plasma in one group and the other group will be closed without infiltration of Platelet rich plasma

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: March 31, 2020
• Est. primary completion date: March 31, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Disrupted surgical wounds after cesarean sections and other gynecological operations

• Body mass index 18-25

• Hemoglobin > 10.5gm/dl

• Albumin >3.5gm/dl

Exclusion Criteria:

• Medical disorders asDiabetes mellitus (DM), Liver disease or systemic lupus erythymatosus (SLE)

• Patient on corticosteriod therapy

• Thrombocytopenia

• Coagulation disorders

Related Conditions & MeSH terms

• Role of Platelet Rich Plasma in Wound Healing
• Surgical Wound
• Wounds and Injuries

Intervention

Procedure:
• Platelet rich plasma infiltration in the wound edges
platelet rich plasma will be injected in the wound edges
• Closure of wound without platelet rich plasma infiltration
No infiltration of platelet rich plasma is done

Locations

Country	Name	City	State
Egypt	Ayman Shehata Dawood	Tanta

Sponsors (1)

Lead Sponsor	Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete wound healing	time needed for complete wound closure	30 days
Primary	Duration of hospital stay	Time during which patient is admitted	30 days
Secondary	Failure of complete wound healing	No complete closure	30 days
Secondary	Need fo tertiary suture	need to re-operate the case again	30 days